Vera Therapeutics, Inc.

Immunology biotech commercializing atacicept for IgA nephropathy while continuing Phase 3 development toward full approval.

Back to company catalog

Immunology / kidney disease · BAFF/APRIL-targeting fusion protein · Commercial (accelerated approval) + Phase 3 confirmatory

Compare report options